Generic entry timeline

Spy Agent Green Kit generics — when can they launch?

Spy Agent Green Kit (INDOCYANINE GREEN) · Renew Pharms · 5 active US patents · 0 expired

Earliest patent expiry
2028-06-04
2 years remaining
Full patent estate to
2039-07-14
complete protection through 2039
FDA approval
1959
Renew Pharms

Where Spy Agent Green Kit sits in the generic timeline

Imminent generic cliff: earliest active US patent for Spy Agent Green Kit expires in 2028 (~2 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Method of Use — 4 patents
  • Formulation — 1 patent

FDA U-codes carved out by Spy Agent Green Kit patents

Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.

U-codeDescription
U-2462(no description)
U-2468(no description)
U-2463(no description)
U-2815(no description)

Sample patent estate

Showing 5 of 5 active US patents. View full estate on the Spy Agent Green Kit drug page →

  • US8185176 Method of Use · expires 2028-06-04
    This patent protects methods and systems for neurovascular imaging.
    USPTO title: Method and apparatus for vasculature visualization with applications in neurosurgery and neurology
  • US8647605 Method of Use · expires 2029-02-11
    This patent protects methods and systems for imaging vessels in a subject, particularly in relation to solid organ transplants.
    USPTO title: Real time imaging during solid organ transplant
  • US8406860 Method of Use · expires 2029-04-09
    This patent protects a method for evaluating the amount of blood flow in heart tissue by analyzing fluorescence signals from images.
    USPTO title: Method for evaluating blush in myocardial tissue
  • US10631746 Method of Use · expires 2035-08-04
    This patent protects a method and apparatus for measuring changes in blood flow in tissue using a fluorescence agent and photoplethysmography.
    USPTO title: Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
  • US11712320 Formulation · expires 2039-07-14
    This patent protects a surgical system that automatically enhances video images of a surgical site and controls recording based on certain conditions or events.
    USPTO title: Methods and systems to automate surgical interventions

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on Spy Agent Green Kit — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →